Clinical Trial Update: Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating once-weekly paclitaxel (BMS-181339) for advanced or recurrent head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Paclitaxel (BMS-181339) (paclitaxel)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED